Transport of the drug into CML cells is via the human organic cation transporter-1 (OCT-1) and low OCT-1 functional activity is associated with treatment resistance and poor patient outcomes [117]. The gene discussed is SLC22A1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.